SCHEMBL5264487

SCHEMBL5264487

COc1cccc(OC)c1NC(=O)c1ccc(Oc2cc3c(cc2C)OCC[Si]3(C)C)o1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR4 O95977 7/20 0.42
S1PR2 O95136 3/20 0.42
S1PR3 Q99500 2/20 0.42
S1PR1 P21453 1/20 0.42
S1PR5 Q9H228 1/20 0.42
GNRHR P30968 2/20 0.39
FPR1 P21462 1/20 0.39
GPR183 P32249 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
CACNA1F O60840 1/20 0.37
CHRM4 P08173 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
CHRM1 P11229 1/20 0.37
CYP2C9 P11712 1/20 0.37
DRD1 P21728 1/20 0.37
DRD4 P21917 1/20 0.37
SLC6A2 P23975 1/20 0.37
HRH2 P25021 1/20 0.37
TACR1 P25103 1/20 0.37
PTAFR P25105 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5264786 0.92 GNRHR (0.47) S1PR4S1PR2S1PR3S1PR1S1PR5
SCHEMBL5266111 0.90 S1PR4 (0.45) S1PR4S1PR2S1PR3S1PR1S1PR5
SCHEMBL5265790 0.87 S1PR4 (0.43) S1PR4S1PR2S1PR3S1PR1S1PR5
SCHEMBL5269013 0.86 GNRHR (0.45) S1PR4S1PR2S1PR3S1PR1S1PR5
SCHEMBL5267717 0.86 S1PR4 (0.45) S1PR4S1PR2S1PR3S1PR1S1PR5
SCHEMBL5268530 0.85 S1PR4 (0.42) S1PR4S1PR2S1PR3S1PR1S1PR5
SCHEMBL5266315 0.85 S1PR4 (0.43) S1PR4S1PR2S1PR3S1PR1S1PR5
SCHEMBL5264917 0.85 S1PR4 (0.41) S1PR4S1PR2S1PR3S1PR1S1PR5
SCHEMBL5264010 0.85 GNRHR (0.47) S1PR4S1PR2S1PR3S1PR1S1PR5
SCHEMBL5264724 0.84 S1PR4 (0.42) S1PR4S1PR2S1PR3S1PR1S1PR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648906-B1 ORGANOSILICON COMPOUNDS AND THEIR USE TAKEDA CAMBRIDGE LTD (GB) 2007-10-03 EP claimed
US-20070111967-A1 Organosilicon compounds and their use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-17 US claimed
EP-1648906-B1 ORGANOSILICON COMPOUNDS AND THEIR USE TAKEDA CAMBRIDGE LTD (GB) 2007-10-03 EP disclosed
US-20070111967-A1 Organosilicon compounds and their use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-17 US disclosed
US-20070111967-A1 Organosilicon compounds and their use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070111967-A1 Organosilicon compounds and their use CYP2B6, UGT1A6, CYP2D6 S1PR4 3988/4885S1PR2 3593/4885S1PR3 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.